Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated
